Cerebral cavernous malformations as a disease of vascular permeability: From bench to bedside with caution

Neurosurgical Focus

Volumn 29, Issue 3, 2010, Pages 1-7

  Yadla, Sanjay ^a   Jabbour, Pascal M ^a   Shenkar, Robert ^b   Shi, Changbin ^b   Camp bell, Peter G ^a   Awad, Issam A ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Angiogenesis; CCM1; CCM2; CCM3; Cerebral cavernous malformation; Endothelial cell junction; Genetics

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; CARRIER PROTEIN; CCM2 PROTEIN, HUMAN; KRIT1 PROTEIN, HUMAN; MEMBRANE PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; ONCOPROTEIN; PDCD10 PROTEIN, HUMAN;

BRAIN ARTERIOVENOUS MALFORMATION; BRAIN HEMANGIOMA; CAPILLARY PERMEABILITY; CELL JUNCTION; GENETICS; HUMAN; METABOLISM; MUTATION; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; VASCULAR ENDOTHELIUM;

APOPTOSIS REGULATORY PROTEINS; CAPILLARY PERMEABILITY; CARRIER PROTEINS; ENDOTHELIUM, VASCULAR; HEMANGIOMA, CAVERNOUS, CENTRAL NERVOUS SYSTEM; HUMANS; INTERCELLULAR JUNCTIONS; INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; MEMBRANE PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS;

EID: 77956215617     PISSN: None     EISSN: 10920684     Source Type: Journal    
DOI: 10.3171/2010.5.FOCUS10121     Document Type: Article

References (82)

1. Adams VR, Leggas M. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther 29:1338-1353, 2007
2. Aiba T, Tanaka R, Koike T, Kameyama S, Takeda N, Komata T. Natural history of intracranial cavernous malformations. J Neurosurg 83:56-59, 1995
3. Akers AL, Johnson E, Steinberg GK, Zabramski JM, Marchuk DA. Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesis. Hum Mol Genet 18:919-930, 2009
4. Al-Shahi R, Bhattacharya JJ, Currie DG, Papanastassiou V, Ritchie V, Roberts RC, et al. Prospective, population-based detection of intracranial vascular malformations in adults: the Scottish Intracranial Vascular Malformation Study (SIVMS). Stroke 34:1163-1169, 2003
5. Awad IA. Unfolding knowledge on cerebral cavernous malformations. Surg Neurol 63:317-318, 2005
6. Batra S, Lin D, Recinos PF, Zhang J, Rigamonti D. Cavernous malformations: natural history, diagnosis and treatment. Nat Rev Neurol 5:659-670, 2009
7. Bergametti F, Denier C, Labauge P, Arnoult M, Boetto S, Clanet M, et al. Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations. Am J Hum Genet 76:42-51, 2005
8. Bicknell JM, Carlow TJ, Kornfeld M, Stovring J, Turner P. Familial cavernous angiomas. Arch Neurol 35:746-749, 1978
9. Boulday G, Blécon A, Petit N, Chareyre F, Garcia LA, NiwaKawakita M, et al. Tissue-specific conditional CCM2 knockout mice establish the essential role of endothelial CCM2 in angiogenesis: implications for human cerebral cavernous malformations. Dis Model Mech 2:168-177, 2009
10. Campeau NG, Lane JI. De novo development of a lesion with the appearance of a cavernous malformation adjacent to an existing developmental venous anomaly. AJNR Am J Neuroradiol 26:156-159, 2005
11. Cavé-Riant F, Denier C, Labauge P, Cécillon M, Maciazek J, Joutel A, et al. Spectrum and expression analysis of KRIT1 mutations in 121 consecutive and unrelated patients with cerebral cavernous malformations. Eur J Hum Genet 10:733- 740, 2002
12. Chen L, Tanriover G, Yano H, Friedlander R, Louvi A, Gunel M. Apoptotic functions of PDCD10/CCM3, the gene mutated in cerebral cavernous malformation Stroke 40:1474-1481, 2009
13. Clark JV. Familial occurrence of cavernous angiomata of the brain. J Neurol Neurosurg Psychiatry 33:871-876, 1970
14. Clatterbuck RE, Eberhart CG, Crain BJ, Rigamonti D. Ultrastructural and immunocytochemical evidence that an incompetent blood-brain barrier is related to the pathophysiology of cavernous malformations. J Neurol Neurosurg Psychiatry 71:188-192, 2001
15. Cohen DS, Zubay GP, Goodman RR. Seizure outcome after lesionectomy for cavernous malformations. J Neurosurg 83: 237-242, 1995
16. Czubayko M, Knauth P, Schlüter T, Florian V, Bohnensack R. Sorting nexin 17, a non-self-assembling and a PtdIns(3)P high class affinity protein, interacts with the cerebral cavernous malformation related protein KRITBiochem Biophys Res Commun 345:1264-1272, 2006
17. Dashti SR, Hoffer A, Hu YC, Selman WR. Molecular genetics of familial cerebral cavernous malformations. Neurosurg Focus 21(1):e2, 2006
18. Denier C, Gasc JM, Chapon F, Domenga V, Lescoat C, Joutel A, et al. Krit1/cerebral cavernous malformation 1 mRNA is preferentially expressed in neurons and epithelial cells in embryo and adult. Mech Dev 117:363-367, 2002
19. Denier C, Goutagny S, Labauge P, Krivosic V, Arnoult M, Cousin A, et al. Mutations within the MGC4607 gene cause cerebral cavernous malformations. Am J Hum Genet 74: 326-337, 2004
20. Denier C, Labauge P, Bergametti F, Marchelli F, Riant F, Arnoult M, et al. Genotype-phenotype correlations in cerebral cavernous malformations patients. Ann Neurol 60:550-556, 2006
21. Denier C, Labauge P, Brunereau L, Cavé-Riant F, Marchelli F, Arnoult M, et al. Clinical features of cerebral cavernous malformations patients with KRIT1 mutations. Ann Neurol 55:213-220, 2004
22. Drigo P, Mammi I, Battistella PA, Ricchieri G, Carollo C. Familial cerebral, hepatic, and retinal cavernous angiomas: a new syndrome. Childs Nerv Syst 10:205-209, 1994
23. Dubovsky J, Zabramski JM, Kurth J, Spetzler RF, Rich SS, Orr HT, et al. A gene responsible for cavernous malformations of the brain maps to chromosome 7q. Hum Mol Genet 4:453-458, 1995
24. Ferroli P, Casazza M, Marras C, Mendola C, Franzini A, Broggi G. Cerebral cavernomas and seizures: a retrospective study on 163 patients who underwent pure lesionectomy. Neurol Sci 26:390-394, 2006
25. Fidalgo M, Fraile M, Pires A, Force T, Pombo C, Zalvide J. CCM3/PDCD10 stabilizes GCKIII proteins to promote Gol-gi assembly and cell orientation. J Cell Sci 123:1274-1284, 2010
26. Francalanci F, Avolio M, De Luca E, Longo D, Menchise V, Guazzi P, et al. Structural and functional differences between KRIT1A and KRIT1B isoforms: a framework for understanding CCM pathogenesis. Exp Cell Res 315:285-303, 2009
27. Gangemi M, Maiuri F, Donati P, Cinalli G, De Caro M, Sigona L. Familial cerebral cavernous angiomas. Neurol Res 12: 131-136, 1990
28. Gault J, Awad IA, Recksiek P, Shenkar R, Breeze R, Handler M, et al. Cerebral cavernous malformations: somatic mutations in vascular endothelial cells. Neurosurgery 65:138-145, 2009
29. Glading A, Han J, Stockton RA, Ginsberg MH. KRIT-1/CCM1 is a Rap1 effector that regulates endothelial cell cell junctions. J Cell Biol 179:247-254, 2007
30. Gross BA, Batjer HH, Awad IA, Bendok BR. Brainstem cavernous malformations. Neurosurgery 64:E805-E818, 2009
31. Guarnieri V, Muscarella LA, Amoroso R, Quattrone A, Abate ME, Coco M, et al. Identification of two novel mutations and of a novel critical region in the KRIT1 gene. Neurogenetics 8:29-37, 2007
32. Guzeloglu-Kayisli O, Amankulor NM, Voorhees J, Luleci G, Lifton RP, Gunel M. KRIT1/cerebral cavernous malformation 1 protein localizes to vascular endothelium, astrocytes, and pyramidal cells of the adult human cerebral cortex. Neurosurgery 54:943-949, 2004
33. Hayman LA, Evans RA, Ferrell RE, Fahr LM, Ostrow P, Riccardi VM. Familial cavernous angiomas: natural history and genetic study over a 5-year period. Am J Med Genet 11:147- 160, 1982
34. Ikeda K, Hosozawa KI, Kashihara H, Kuratomi S, Kumazawa J, Shioikari M, et al. Familial cavernous angiomas. Neurology 64:163, 2005
35. Kuhn J, Brümmendorf TH, Brassat U, Lehnhardt FG, Chung BD, Harnier S, et al. Novel KRIT1 mutation and no molecular evidence of anticipation in a family with cerebral and spinal cavernous malformations. Eur Neurol 61:154-158, 2009
36. Labauge P. [Familial forms of central nervous system cavernomas: from recognition to gene therapy.] Neurochirurgie 53:152-155, 2007 (Fr)
37. Laberge-le Couteulx S, Jung HH, Labauge P, Houtteville JP, Lescoat C, Cecillon M, et al. Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas. Nat Genet 23:189-193, 1999
38. Larson JJ, Ball WS, Bove KE, Crone KR, Tew JM Jr. Formation of intracerebral cavernous malformations after radiation treatment for central nervous system neoplasia in children. J Neurosurg 88:51-56, 1998
39. Leblanc GG, Golanov E, Awad IA, Young WL. Biology of vascular malformations of the brain. Stroke 40:e694-e702, 2009
40. Lee KS, Spetzler RF. Cerebral cavernous malformations. Arch Neurol 46:1273, 1989 (Letter)
41. Liquori CL, Berg MJ, Siegel AM, Huang E, Zawistowski JS, Stoffer T, et al. Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations. Am J Hum Genet 73: 1459-1464, 2003
42. Liquori CL, Berg MJ, Squitieri F, Leedom TP, Ptacek L, Johnson EW, et al. Deletions in CCM2 are a common cause of cerebral cavernous malformations. Am J Hum Genet 80:69- 75, 2007
43. Liquori CL, Berg MJ, Squitieri F, Ottenbacher M, Sorlie M, Leedom TP, et al. Low frequency of PDCD10 mutations in a panel of CCM3 probands: potential for a fourth CCM locus. Hum Mutat 27:118, 2006
44. Lucas M, Costa AF, Montori M, Solano F, Zayas MD, Izquierdo G. Germline mutations in the CCM1 gene, encoding Krit1, cause cerebral cavernous malformations. Ann Neurol 49: 529-532, 2001
45. Maiuri F, Cappabianca P, Gangemi M, De Caro MdelB, Esposito F, Pettinato G, et al. Clinical progression and familial occurrence of cerebral cavernous angiomas: the role of angiogenic and growth factors. Neurosurg Focus 21(1):e3, 2006
46. Mason I, Aase JM, Orrison WW, Wicks JD, Seigel RS, Bicknell JM. Familial cavernous angiomas of the brain in an Hispanic family. Neurology 38:324-326, 1988
47. Meanwell NA, Kadow JF. Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS. Curr Opin Investig Drugs 8:669-681, 2007
48. Mena AC, Pulido EG, Guillén-Ponce C. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anticancer Drugs 21 (Suppl 1):S3-S11, 2010
49. Moen MD, McKeage K, Plosker GL, Siddiqui MA. Imatinib: a review of its use in chronic myeloid leukaemia. Drugs 67: 299-320, 2007
50. Moriarity JL, Wetzel M, Clatterbuck RE, Javedan S, Sheppard JM, Hoenig-Rigamonti K, et al. The natural history of cavernous malformations: a prospective study of 68 patients. Neurosurgery 44:1166-1173, 1999
51. Nimjee SM, Powers CJ, Bulsara KR. Review of the literature on de novo formation of cavernous malformations of the central nervous system after radiation therapy. Neurosurg Focus 21(1):e4, 2006
52. Noto S, Fujii M, Akimura T, Imoto H, Nomura S, Kajiwara K, et al. Management of patients with cavernous angiomas presenting epileptic seizures. Surg Neurol 64:495-499, 2005
53. Ojemann RG, Ogilvy CS. Microsurgical treatment of supratentorial cavernous malformations. Neurosurg Clin N Am 10:433-440, 1999
54. Pagenstecher A, Stahl S, Sure U, Felbor U. A two-hit mechanism causes cerebral cavernous malformations: complete inactivation of CCM1, CCM2 or CCM3 in affected endothelial cells. Hum Mol Genet 18:911-918, 2009
55. Patterson C. Torturing a blood vessel. Nat Med 15:137-138, 2009
56. Perrini P, Lanzino G. The association of venous developmental anomalies and cavernous malformations: pathophysiological, diagnostic, and surgical considerations. Neurosurg Focus 21(1):e5, 2006
57. Petersen TA, Morrison LA, Schrader RM, Hart BL. Familial versus sporadic cavernous malformations: differences in developmental venous anomaly association and lesion phenotype. AJNR Am J Neuroradiol 31:377-382, 2010
58. Petit N, Blécon A, Denier C, Tournier-Lasserve E. Patterns of expression of the three cerebral cavernous malformation (CCM) genes during embryonic and postnatal brain development. Gene Expr Patterns 6:495-503, 2006
59. Pham M, Gross BA, Bendok BR, Awad IA, Batjer HH. Radiosurgery for angiographically occult vascular malformations. Neurosurg Focus 26(5):E16, 2009
60. Plummer NW, Gallione CJ, Srinivasan S, Zawistowski JS, Louis DN, Marchuk DA. Loss of p53 sensitizes mice with a mutation in Ccm1 (KRIT1) to development of cerebral vascular malformations. Am J Pathol 165:1509-1518, 2004
61. Revencu N, Vikkula M. Cerebral cavernous malformation: new molecular and clinical insights. J Med Genet 43:716- 721, 2006
62. Rigamonti D, Drayer BP, Johnson PC, Hadley MN, Zabramski J, Spetzler RF. The MRI appearance of cavernous malformations (angiomas). J Neurosurg 67:518-524, 1987
63. Russell DS, Rubinstein LJ (eds). Pathology of Tumours of the Nervous System, ed 5. Baltimore: Williams & Wilkins, 1989
64. Sayana S, Khanlou H. Maraviroc: a new CCR5 antagonist. Expert Rev Anti Infect Ther 7:9-19, 2009
65. Seker A, Pricola KL, Guclu B, Ozturk AK, Louvi A, Gunel M. CCM2 expression parallels that of CCMStroke 37:518- 523, 2006
66. Serebriiskii I, Estojak J, Sonoda G, Testa JR, Golemis EA. Association of Krev-1/rap1a with Krit1, a novel ankyrin repeatcontaining protein encoded by a gene mapping to 7q21-22 Oncogene 15:1043-1049, 1997
67. Shenkar R, Venkatasubramanian PN, Wyrwicz AM, Zhao JC, Shi C, Akers A, et al. Advanced magnetic resonance imaging of cerebral cavernous malformations: part II. Imaging of lesions in murine models. Neurosurgery 63:790-798, 2008
68. Shi C, Shenkar R, Batjer HH, Check IJ, Awad IA. Oligoclonal immune response in cerebral cavernous malformations. Laboratory investigation. J Neurosurg 107:1023-1026, 2007
69. Shi C, Shenkar R, Du H, Duckworth E, Raja H, Batjer HH, et al. Immune response in human cerebral cavernous malformations. Stroke 40:1659-1665, 2009
70. Stockton RA, Shenkar R, Awad IA, Ginsberg MH. Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. J Exp Med 207:881-896, 2010
71. Tan PH, Manunta M, Ardjomand N, Xue SA, Larkin DF, Haskard DO, et al. Antibody targeted gene transfer to endothelium. J Gene Med 5:311-323, 2003
72. Tanriover G, Seval Y, Sati L, Gunel M, Demir N. CCM2 and CCM3 proteins contribute to vasculogenesis and angiogenesis in human placenta. Histol Histopathol 24:1287-1294, 2009
73. Trepel M, Grifman M, Weitzman MD, Pasqualini R. Molecular adaptors for vascular-targeted adenoviral gene delivery. Hum Gene Ther 11:1971-1981, 2000
74. Tu J, Stoodley MA, Morgan MK, Storer KP. Ultrastructural characteristics of hemorrhagic, nonhemorrhagic, and recurrent cavernous malformations. J Neurosurg 103:903-909, 2005
75. Voss K, Stahl S, Schleider E, Ullrich S, Nickel J, Mueller TD, et al. CCM3 interacts with CCM2 indicating common pathogenesis for cerebral cavernous malformations. Neurogenetics 8:249-256, 2007
76. Whitehead KJ, Chan AC, Navankasattusas S, Koh W, London NR, Ling J, et al. The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases. Nat Med 15:177-184, 2009 (Erratum in Nat Med 15:462, 2009)
77. Whitehead KJ, Plummer NW, Adams JA, Marchuk DA, Li DY. Ccm1 is required for arterial morphogenesis: implications for the etiology of human cavernous malformations. Development 131:1437-1448, 2004
78. Wong JH, Awad IA, Kim JH. Ultrastructural pathological features of cerebrovascular malformations: a preliminary report. Neurosurgery 46:1454-1459, 2000
79. Zawistowski JS, Stalheim L, Uhlik MT, Abell AN, Ancrile BB, Johnson GL, et al. CCM1 and CCM2 protein interactions in cell signaling: implications for cerebral cavernous malformations pathogenesis. Hum Mol Genet 14:2521-2531, 2005
80. Zevgaridis D, van Velthoven V, Ebeling U, Reulen HJ. Seizure control following surgery in supratentorial cavernous malformations: a retrospective study in 77 patients. Acta Neurochir (Wien) 138:672-677, 1996
81. Zhang J, Basu S, Rigamonti D, Dietz HC, Clatterbuck RE. Krit1 modulates beta 1-integrin-mediated endothelial cell proliferation. Neurosurgery 63:571-578, 2008
82. Zhang J, Rigamonti D, Dietz HC, Clatterbuck RE. Interaction between krit1 and malcavernin: implications for the pathogenesis of cerebral cavernous malformations. Neurosurgery 60:353-359, 2007